Recursion Pharmaceuticals Inc (NASDAQ: RXRX) is a clinical-stage biopharmaceutical company that uses an AI-native platform to discover and develop drug candidates. The company describes its platform as an end-to-end AI-native operating system for creating medicines, integrating biological data generation with machine learning to identify potential therapeutics. As of the 10-K filed February 25, 2026 covering fiscal year ended 2025, Recursion characterizes 2025 as an inflection point where its AI platform began producing clinical-stage results. The company is pre-profitability and has not disclosed segment revenue breakdowns or named commercial products in the available filing excerpts. Class A and Class B common stock are outstanding as of January 31, 2026, with the aggregate market value of non-affiliate Class A shares measured as of June 30, 2025.

Revenue model

The available filing excerpts do not provide sufficient detail on specific revenue streams, partnership economics, or royalty structures to characterize the revenue model.

Products and services

The filing describes an AI-native platform for drug discovery and development, referred to as an end-to-end AI-native operating system for creating medicines. Specific drug candidates, pipeline programs, or commercial products are not named in the available excerpts.

Customers and end markets

The filing excerpts do not name specific customers, partners, or end markets. The company operates in drug discovery and development, targeting clinical-stage medicine creation.

Value-chain role

Drug discovery and development; AI-enabled preclinical and clinical-stage biopharmaceutical company.

Geographic exposure

The available filing excerpts do not specify geographic revenue mix or operational footprint beyond the company being listed on the Nasdaq Stock Exchange.

Source: SEC 10-K, filed 2026-02-25

Industry: Biological Products, (No Diagnostic Substances) Peers: Allogene Therapeutics Inc Arcus Biosciences Inc Immunitybio Inc Ironwood Pharmaceuticals Inc IVERIC bio, Inc. Krystal Biotech Inc Lyell Immunopharma Inc Revolution Medicines Inc Verve Therapeutics, Inc.